NLRP3 and Gut-Liver Axis: New Possibility for the Treatment of Alcohol-Associated Liver Disease

被引:0
|
作者
Dong, Lu [1 ]
Zhang, Haotian [1 ]
Kang, Yanyu [1 ]
Wang, Fei [1 ]
Bai, Ting [1 ]
Yang, Yong [1 ]
机构
[1] Dalian Univ, Dalian Key Lab Chron Dis Res Ctr, Dalian, Liaoning, Peoples R China
关键词
alcohol-associated liver disease; bile acid; gut microbiota; gut-liver axis; inflammasome; NLRP3; INFLAMMASOME; BILE; MICROBIOME; ACTIVATION;
D O I
10.1111/jgh.16935
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Alcohol-associated liver disease (ALD) is one of the most prevalent chronic diseases worldwide, with persistently high morbidity and mortality rates. Previous studies have identified NLRP3 inflammasome as a class of receptors of intracellular intrinsic immunity. These receptors can be activated by both intrinsic and extracellular danger signals, leading to the release of downstream pro-inflammatory factors, including interleukin IL-1 beta and IL-18. These vesicles are critical for maintaining host defense. Concurrently, researchers have identified a close relationship between the microbiome, gut-liver axis, and NLRP3 inflammasome with ALD. Consequently, the present study focus on the structure and activation of the NLRP3 inflammasome, the gut-liver axis, and intestinal microecological regulation, as well as the relationship between bile acid metabolism and the gut-liver axis. The objective of this study is to provide a foundation of knowledge and references for the development of targeted therapeutic interventions of ALD that are informed by the dynamic interplay between the NLRP3 inflammasome and the gut-liver axis.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Intestinal Bacterial Dysbiosis and Liver Fibrosis in Mice Through Gut-Liver Axis and NLRP3 Inflammatory Pathway Caused by Fine Particulate Matter
    Fu, Pengfei
    Zhang, Mei
    Bai, Lirong
    Chen, Shanshan
    Chen, Wenqi
    Li, Zhiping
    Yue, Jianwei
    Dong, Chuan
    Li, Ruijin
    JOURNAL OF APPLIED TOXICOLOGY, 2025,
  • [32] Diagnosis and Treatment of Alcohol-Associated Liver Disease A Review
    Singal, Ashwani K.
    Mathurin, Philippe
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (02): : 165 - 176
  • [33] Alcohol-Associated Liver Disease - From Pathogenesis to Treatment
    Singal, Ashwani K.
    Anand, Anil C.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 13 (03) : 387 - 389
  • [34] Elafibranor: A promising treatment for alcohol-associated liver disease?
    Wei, Hong
    Sang, Li-Xuan
    Chang, Bing
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (39)
  • [35] A Review of the Diagnosis and Treatment of Alcohol-Associated Liver Disease
    Conteh, Lanla
    Levin, Douglas
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (19): : 1976 - 1976
  • [36] Targeting pathobionts for the treatment of alcohol-associated liver disease
    Lang, Sonja
    Demir, Muenevver
    Schnabl, Bernd
    LIVER INTERNATIONAL, 2021, 41 (01) : 239 - 240
  • [37] Current Medical Treatment for Alcohol-Associated Liver Disease
    Ayares, Gustavo
    Idalsoaga, Francisco
    Diaz, Luis A.
    Arnold, Jorge
    Arab, Juan P.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 12 (05) : 1333 - 1348
  • [38] Melatonin improves cholestatic liver disease via the gut-liver axis
    Liu, Xianjiao
    Li, Jinyan
    Shi, Mengdie
    Fu, Jun
    Wang, Yubo
    Kang, Weili
    Liu, Jinyan
    Zhu, Fenxia
    Huang, Kehe
    Chen, Xingxiang
    Liu, Yunhuan
    JOURNAL OF PINEAL RESEARCH, 2024, 76 (01)
  • [39] Galangin alleviates alcoholic liver disease by regulating the gut-liver axis
    Duan, Dongzhu
    Du, Zhenzhen
    Zhao, Ling
    JOURNAL OF FUNCTIONAL FOODS, 2024, 122
  • [40] Commentary on the gut microbiome in alcohol use disorder and alcohol-associated liver disease
    Llorente, Cristina
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 48 (08): : 1466 - 1468